BioMarin's drug shows significant growth gains in children in late-stage trial

BioMarin said its rare-disease treatment met the primary endpoint in a late-stage study, boosting growth in children with short stature. The positive clinical result sent shares up nearly 5% in extended trading. The update supports the drug's commercial prospects and strengthens the company's pipeline narrative.

Analysis

BioMarin said its rare-disease treatment met the primary endpoint in a late-stage study, boosting growth in children with short stature. The positive clinical result sent shares up nearly 5% in extended trading. The update supports the drug's commercial prospects and strengthens the company's pipeline narrative.